NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization13,650 mln
Float153 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.66
Highly suspicious
1-Year Forecast
102
Exceptional upside
Relative Strength
78
/ 100
Strongly outperforming
Debt / Equity
-1.09
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
BridgeBio Pharma is a drug development company focused on finding and delivering treatments for patients with inherited genetic conditions. Founded in 2015 and based in Palo Alto, California, the company has several medicines either already on the market or in late-stage clinical testing, targeting conditions that affect the heart, bones, muscles, and other systems. BridgeBio works alongside partners including Bayer, Alexion, Novartis, and Stanford University to advance its pipeline of therapies.
